ArticleCancer reports (Hoboken, N.J.)2025
Arjunolic Acid From Terminalia ivorensis A. Chev (Combretaceae) Possesses Anti-Breast Cancer Effects In Vitro and In Vivo.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pentacyclic Triterpenoid Acids in the Treatment of Breast Cancer.Molecules (Basel, Switzerland) · 2026Review
- Arjunolic Acid From Terminalia ivorensis A. Chev (Combretaceae) Possesses Anti-Breast Cancer Effects In Vitro and In Vivo.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundBreast cancer is a major public health issue. In 2022, approximately 4,207 new cases and 2,285 deaths were reported in Cameroon. Given the limited accessibility and various issues associated with conventional treatments, herbal medicine has emerged as a promising alternative.
aimsThis study aimed to evaluate the potential anticancer activity of naturally occurring compounds isolated from Terminalia ivorensis A. Chev. METHODS AND
resultsThis was done by fractionating the methanolic extract of T. ivorensis and purifying the constituents obtained using conventional chromatographic techniques. Thereafter, the crude extract and its 5 isolates were subjected to in vitro MTT bioassay to assess their potential to kill human (MCF-7 and MDA-MB-231) and murine (4T1) breast cancer cell lines. Furthermore, the potential of the most active compound (arjunolic acid) to mitigate DMBA-induced breast cancer in rats was tested. Treatments were administered for a period of 121 days; the group of rats treated with arjunolic acid (1 mg/kg) was compared to the group that received tamoxifen at 3.3 mg/kg (standard), as well as to the normal and negative control groups. Key parameters assessed included survival, tumor burden, cytokine profiles, as well as hematological, hepatic, and renal functions. Out of the 5 isolates [lupeol (1), betulinic acid (2), Arjunolic acid (3), 3,3'-Di-O-methylellagic acid-4'-O-β-D-glucopyranoside (4) 3,3',4'-Tri-O-methylellagic acid-4-O-β-Dglucopyranoside (5)] from T. ivorensis, compound (3) had the most significant inhibitory effect against breast cancer cells growth with an average CC50 of 20 μg/mL. In vivo, a significant reduction (~89%) in tumor burden and favorable modulation of inflammation, characterized by a decrease in pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6, VEGF) and an increase in anti-inflammatory IL-10 was observed. Moreover, treatment with arjunolic acid led to improved survival and maintenance of body weight, without inducing any notable adverse effects.
conclusionArjunolic acid should receive more attention as a candidate for an effective therapeutic option, combining anticancer effects with beneficial anti-inflammatory activity. We encourage further studies on this compound to better understand its mode and mechanism of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.